Musetti SN, Huang L. Tinagl1 gene therapy suppresses growth and remodels the microenvironment of triple negative breast cancer. Mol Pharm. 2021 May 3;18(5):2032-8. doi: 10.1021/acs.molpharmaceut.1c00008
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Kosa KM, Cates SC, Hall AJ, Brophy JE, Frasier A. Knowledge of norovirus prevention and control among infection preventionists. Poster presented at the 2014 APIC’s 41st Annual Conference; June 2014. Anaheim, CA. [abstract] Am J Infect Control. 2014 Jun; 42(6):676-8. doi: 10.1016/j.ajic.2014.02.004
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011 May 1;39(4):e15-20.
Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010 Feb;38(1):44-9. doi: 10.1016/j.ajic.2009.04.287.